The agenda features a mix of clinical updates and lively debates on provocative scientific topics in the field, including emerging concepts and therapies in multiple myeloma, lymphoma, acute and chronic lymphocytic leukemia, myeloid malignancies, and much more.

Agenda

July 27-28 | Los Angeles

Available DatesRegister

April 5-6 | New York City

July 27-28 | Los Angeles

May 11 | Myeloma Day | Dallas

Saturday July 27, 2024

8:00 AM – 8:05 AM
Welcome
- Co-Chair
  - John LeonardMD
8:05 AM – 8:20 AM
Session 1: Debate- Chemotherapy-Based Approaches Are Best for Initial Therapy for Mantle Cell Lymphoma
- Speaker
  - Elizabeth BremMD
8:20 AM – 8:35 AM
Session 1: Debate- Novel, Non-chemotherapy Approaches are Best for Initial Therapy for Mantle Cell Lymphoma
- Speaker
  - Tycel PhillipsMD
8:35 AM – 8:45 AM
Session 1: PANEL DISCUSSION
- Moderator
  - John LeonardMD
- Panelist
  - Elizabeth BremMD
  - Tycel PhillipsMD
8:45 AM – 9:00 AM
Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive CAR-T Cell Therapy?
- Speaker
  - Mazyar ShadmanMD, MPH
9:00 AM – 9:15 AM
Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive Novel Agents?
- Speaker
  - Elizabeth BremMD
9:15 AM – 9:25 AM
Session 2: PANEL DISCUSSION
- Moderator
  - John LeonardMD
- Panelist
  - Elizabeth BremMD
  - Mazyar ShadmanMD, MPH
9:25 AM – 9:55 AM
Session 3: Reevaluating Frontline Therapy and Beyond for Hodgkin Lymphoma: Strategies for Optimal Clinical Decision-Making and Targeted Therapy Across Patient Groups
- Speaker
  - Tycel PhillipsMD
9:55 AM – 10:05 AM
Session 3: Post Session Survey and Q&A
- Moderator
  - John LeonardMD
- Speaker
  - Tycel PhillipsMD
10:05 AM – 10:15 AM

Exhibit Hall Break
10:15 AM – 11:15 AM

Breakfast Innovation Theater (Non-Accredited) (Sponsored by Amgen)
11:15 AM – 11:45 AM
Session 4: Targeted Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
- Speaker
  - John AllanMD
11:45 AM – 11:55 AM
Session 4: Post Session Survey and Q&A
- Moderator
  - John LeonardMD
- Panelist
  - John AllanMD
11:55 AM – 12:25 PM
Session 5: Evaluating Targeted Therapeutic Options in Relapsed/Refractory Follicular Lymphoma
- Speaker
  - John LeonardMD
12:25 PM – 12:35 PM
Session 5: Post Session Survey and Q&A
- Moderator
  - John LeonardMD
12:35 PM – 12:45 PM

Exhibit Hall Break
12:45 PM – 1:45 PM

Lunch Innovation Theater (Non-Accredited) (Sponsored by Johnson & Johnson)
1:45 PM – 2:15 PM

Exhibit Hall Break
2:15 PM – 2:30 PM
Session 6: Debate- CAR-T Cells Should Be Rarely Used in Relapsed Follicular Lymphoma
- - Sven De VosMD, PhD
2:30 PM – 2:45 PM
Session 6: Debate- CAR-T Cells Should Be More Often Used in Relapsed Follicular Lymphoma
- Speaker
  - Elizabeth BuddeMD, PhD
2:45 PM – 2:55 PM
Session 6: PANEL DISCUSSION
- - Sven De VosMD, PhD
- Moderator
  - John LeonardMD
- Panelist
  - Elizabeth BuddeMD, PhD
2:55 PM – 3:25 PM
Session 7: Case Discussions in Leukemia
- Moderator
  - Naval DaverMD
- Panelist
  - Pinkal DesaiMD
  - Richard StoneMD
  - Yasmin AbazaMD
3:25 PM – 3:35 PM
Session 7: Post Session Survey and Q&A
- Moderator
  - Naval DaverMD
- Panelist
  - Pinkal DesaiMD
  - Richard StoneMD
  - Yasmin AbazaMD
3:35 PM – 4:05 PM

Exhibit Hall Break
4:05 PM – 4:20 PM
Session 8: Transplant considerations for MDS patients undergoing AlloHSCT
- Speaker
  - Brian BallMD, MS
4:20 PM – 4:35 PM
Session 8: Therapeutic Updates for higher risk MDS
- Speaker
  - Yasmin AbazaMD
4:35 PM – 4:45 PM
Session 8: PANEL DISCUSSION
- Moderator
  - Naval DaverMD
- Panelist
  - Brian BallMD, MS
  - Yasmin AbazaMD

Sunday July 28, 2024

8:00 AM – 8:05 AM

Welcome
8:05 AM – 8:20 AM
Session 9: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for Intensive Chemotherapy - YES
- Speaker
  - Curtis LachowiezMD
8:20 AM – 8:35 AM
Session 9: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for Intensive Chemotherapy- NO
- Speaker
  - Richard StoneMD
8:35 AM – 8:45 AM
Session 9: PANEL DISCUSSION
- Moderator
  - Naval DaverMD
- Panelist
  - Curtis LachowiezMD
  - Richard StoneMD
8:45 AM – 9:15 AM
Session 10: Advancing Risk Stratification and Symptom Management in Patients with Low- and Intermediate-Risk Myelodysplastic Syndromes
- Speaker
  - Pinkal DesaiMD
9:15 AM – 9:25 AM
Session 10- Post Session Survey and Q&A
- Moderator
  - Naval DaverMD
9:25 AM – 10:05 AM
Session 11: Special Panel: The Future of Myeloma
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Amrita KrishnanMD FACP
  - Jeffrey MatousMD
  - Jonathan KaufmanMD
10:05 AM – 10:15 AM

Exhibit Hall Break
10:15 AM – 11:15 AM

Breakfast Innovation Theater (Non-Accredited) (Sponsored by Lilly)
11:15 AM – 11:45 AM

Exhibit Hall Break
11:45 AM – 12:00 PM
Session 12: Debate - Stem Cell Transplant Should Be Offered to Patients over 65 - YES
- Speaker
  - Amrita KrishnanMD FACP
12:00 PM – 12:15 PM
Session 12: Debate - Stem Cell Transplant Should Be Offered to Patients over 65 - NO
- Speaker
  - Ajai ChariMD
12:15 PM – 12:25 PM
Session 12: PANEL DISCUSSION
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Ajai ChariMD
  - Amrita KrishnanMD FACP
12:25 PM – 12:55 PM
Session 13: Multiple Myeloma: Strategies to Optimize Frontline Treatment Selection
- Speaker
  - Joseph MikhaelMD, MEd, FRCPC
12:55 PM – 1:05 PM
Session 13: Post Session Survey and Q&A
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
1:05 PM – 2:05 PM

Lunch and Exhibit Hall Break
2:05 PM – 2:35 PM
Session 14: Relapsed/Refractory Multiple Myeloma: Essential Strategies to Optimize the Utility of Novel and Cellular Therapies
- Speaker
  - Jonathan KaufmanMD
2:35 PM – 2:45 PM
Session 14: Post Session Survey and Q&A
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Jonathan KaufmanMD
2:45 PM – 3:00 PM
Session 15: Debate- MRD Should Guide Therapy -YES
- Speaker
  - Rafael FonsecaMD
3:00 PM – 3:15 PM
Session 15: Debate- MRD Should Guide Therapy -No
- Speaker
  - Murali JanakiramMBBS MS
3:15 PM – 3:25 PM
Session 15: PANEL DISCUSSION
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Murali JanakiramMBBS MS
- Speaker
  - Rafael FonsecaMD
3:25 PM – 3:40 PM
Session 16- Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate -YES
- Speaker
  - Ajai ChariMD
3:40 PM – 3:55 PM
Session 16: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate -NO
- Speaker
  - Sarah LeeMD
3:55 PM – 4:05 PM
Session 16: PANEL DISCUSSION
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Ajai ChariMD
  - Sarah LeeMD
4:05 PM – 4:20 PM
Session 17: Debate - CAR T Cell Therapy Should Be Used As Early As Possible - YES
- Speaker
  - Jeffrey MatousMD
4:20 PM – 4:35 PM
Session 17: Debate - CAR T Cell Therapy Should Be Used As Early As Possible - NO
- Speaker
  - Rahul BanerjeeMD
4:35 PM – 4:45 PM
Session 17: PANEL DISCUSSION
- Moderator
  - Joseph MikhaelMD, MEd, FRCPC
- Panelist
  - Jeffrey MatousMD
  - Rahul BanerjeeMD

Available Dates

Agenda

July 27-28 | Los Angeles

Saturday July 27, 2024

Welcome

Session 1: Debate- Chemotherapy-Based Approaches Are Best for Initial Therapy for Mantle Cell Lymphoma

Session 1: Debate- Novel, Non-chemotherapy Approaches are Best for Initial Therapy for Mantle Cell Lymphoma

Session 1: PANEL DISCUSSION

Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive CAR-T Cell Therapy?

Session 2: Debate-Should Older Patients with Relapsed DLBCL Receive Novel Agents?

Session 2: PANEL DISCUSSION

Session 3: Reevaluating Frontline Therapy and Beyond for Hodgkin Lymphoma: Strategies for Optimal Clinical Decision-Making and Targeted Therapy Across Patient Groups

Session 3: Post Session Survey and Q&A

Exhibit Hall Break

Breakfast Innovation Theater (Non-Accredited) (Sponsored by Amgen)

Session 4: Targeted Approaches for Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Session 4: Post Session Survey and Q&A

Session 5: Evaluating Targeted Therapeutic Options in Relapsed/Refractory Follicular Lymphoma

Session 5: Post Session Survey and Q&A

Exhibit Hall Break

Lunch Innovation Theater (Non-Accredited) (Sponsored by Johnson & Johnson)

Exhibit Hall Break

Session 6: Debate- CAR-T Cells Should Be Rarely Used in Relapsed Follicular Lymphoma

Session 6: Debate- CAR-T Cells Should Be More Often Used in Relapsed Follicular Lymphoma

Session 6: PANEL DISCUSSION

Session 7: Case Discussions in Leukemia

Session 7: Post Session Survey and Q&A

Exhibit Hall Break

Session 8: Transplant considerations for MDS patients undergoing AlloHSCT

Session 8: Therapeutic Updates for higher risk MDS

Session 8: PANEL DISCUSSION

Sunday July 28, 2024

Welcome

Session 9: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for Intensive Chemotherapy - YES

Session 9: Debate- It Is the Age of Triplets for Treatment of Adults Who Are Ineligible for Intensive Chemotherapy- NO

Session 9: PANEL DISCUSSION

Session 10: Advancing Risk Stratification and Symptom Management in Patients with Low- and Intermediate-Risk Myelodysplastic Syndromes

Session 10- Post Session Survey and Q&A

Session 11: Special Panel: The Future of Myeloma

Exhibit Hall Break

Breakfast Innovation Theater (Non-Accredited) (Sponsored by Lilly)

Exhibit Hall Break

Session 12: Debate - Stem Cell Transplant Should Be Offered to Patients over 65 - YES

Session 12: Debate - Stem Cell Transplant Should Be Offered to Patients over 65 - NO

Session 12: PANEL DISCUSSION

Session 13: Multiple Myeloma: Strategies to Optimize Frontline Treatment Selection

Session 13: Post Session Survey and Q&A

Lunch and Exhibit Hall Break

Session 14: Relapsed/Refractory Multiple Myeloma: Essential Strategies to Optimize the Utility of Novel and Cellular Therapies

Session 14: Post Session Survey and Q&A

Session 15: Debate- MRD Should Guide Therapy -YES

Session 15: Debate- MRD Should Guide Therapy -No

Session 15: PANEL DISCUSSION

Session 16- Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate -YES

Session 16: Debate- BCMA Therapy Followed by Another BCMA Therapy Is Appropriate -NO

Session 16: PANEL DISCUSSION

Session 17: Debate - CAR T Cell Therapy Should Be Used As Early As Possible - YES

Session 17: Debate - CAR T Cell Therapy Should Be Used As Early As Possible - NO

Session 17: PANEL DISCUSSION

Questions?